ProQR Therapeutics (PRQR) Total Current Liabilities (2021 - 2025)

ProQR Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $41.6 million for Q4 2024.

  • For Q4 2024, Total Current Liabilities rose 12.96% year-over-year to $41.6 million; the TTM value through Dec 2024 reached $41.6 million, up 12.96%, while the annual FY2024 figure was $42.1 million, 13.8% up from the prior year.
  • Total Current Liabilities for Q4 2024 was $41.6 million at ProQR Therapeutics, up from $36.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $41.6 million in Q4 2024 and bottomed at $21.4 million in Q4 2022.
  • The 4-year median for Total Current Liabilities is $34.2 million (2021), against an average of $32.8 million.
  • The largest annual shift saw Total Current Liabilities crashed 32.17% in 2022 before it soared 71.86% in 2023.
  • A 4-year view of Total Current Liabilities shows it stood at $31.6 million in 2021, then tumbled by 32.17% to $21.4 million in 2022, then surged by 71.86% to $36.8 million in 2023, then increased by 12.96% to $41.6 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Total Current Liabilities are $41.6 million (Q4 2024), $36.8 million (Q4 2023), and $21.4 million (Q4 2022).